CCLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CareCloud Inc (CCLD) is not a compelling buy for a beginner, long-term investor at this time. While the company has shown strong financial growth in the latest quarter and has taken steps to improve liquidity and simplify its capital structure, the lack of strong technical signals, neutral trading sentiment, and concerns raised by analysts about underlying revenue declines and questionable acquisitions suggest caution. The stock's recent performance and technical indicators do not present a clear entry point for long-term investment.
The MACD histogram is negative (-0.0736) and contracting, indicating weak momentum. The RSI is neutral at 49.349, and moving averages are converging, showing no clear trend. Key support is at 2.741, and resistance levels are at 3.42 and 3.63. Overall, technical indicators suggest a lack of strong directional momentum.
CareCloud has secured a $50 million credit facility to improve liquidity and support growth initiatives. The company plans to redeem Series B preferred shares, eliminating $3.2 million in annual dividend obligations, and is focusing on expanding its AI-driven healthcare platform.
Analysts have raised concerns about underlying revenue declines masked by acquisitions and the questionable decision to acquire an aircraft for client visits. Additionally, the stock lacks strong trading sentiment, with hedge funds and insiders showing neutral activity.
In Q4 2025, revenue increased by 21.90% YoY to $34.42 million, net income surged by 15130% YoY to $1.52 million, and EPS remained flat at 0.04. However, gross margin dropped by 2.04% YoY to 34.62%.
Roth Capital maintains a Neutral rating with a $3.25 price target, citing 'fair' results but concerns over revenue declines and acquisitions. No recent upgrades or strong buy recommendations.
